JP2018531936A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531936A5 JP2018531936A5 JP2018516772A JP2018516772A JP2018531936A5 JP 2018531936 A5 JP2018531936 A5 JP 2018531936A5 JP 2018516772 A JP2018516772 A JP 2018516772A JP 2018516772 A JP2018516772 A JP 2018516772A JP 2018531936 A5 JP2018531936 A5 JP 2018531936A5
- Authority
- JP
- Japan
- Prior art keywords
- level
- patient
- item
- reg3α
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 415
- 108091034117 Oligonucleotide Proteins 0.000 claims description 188
- 101700026522 SMAD7 Proteins 0.000 claims description 181
- 102000049873 Smad7 Human genes 0.000 claims description 181
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 181
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 181
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 128
- 230000007423 decrease Effects 0.000 claims description 116
- 108010002616 Interleukin-5 Proteins 0.000 claims description 84
- 102000003816 Interleukin-13 Human genes 0.000 claims description 83
- 108090000176 Interleukin-13 Proteins 0.000 claims description 83
- 102100024484 Codanin-1 Human genes 0.000 claims description 33
- 101000980888 Homo sapiens Codanin-1 Proteins 0.000 claims description 33
- 208000004998 Abdominal Pain Diseases 0.000 claims description 28
- 239000007788 liquid Substances 0.000 claims description 28
- 239000002773 nucleotide Substances 0.000 claims description 25
- 125000003729 nucleotide group Chemical group 0.000 claims description 25
- 206010012735 Diarrhoea Diseases 0.000 claims description 20
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 18
- 208000011231 Crohn disease Diseases 0.000 claims description 16
- 231100000682 maximum tolerated dose Toxicity 0.000 claims description 14
- LUCHPKXVUGJYGU-XLPZGREQSA-N 5-methyl-2'-deoxycytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 LUCHPKXVUGJYGU-XLPZGREQSA-N 0.000 claims description 10
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 10
- 238000002965 ELISA Methods 0.000 claims description 10
- 101000652166 Homo sapiens Mothers against decapentaplegic homolog 7 Proteins 0.000 claims description 10
- 108090001007 Interleukin-8 Proteins 0.000 claims description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 10
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 10
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 10
- 238000004458 analytical method Methods 0.000 claims description 10
- 102000044356 human SMAD7 Human genes 0.000 claims description 10
- 239000003246 corticosteroid Substances 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 238000012544 monitoring process Methods 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 229960001334 corticosteroids Drugs 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims 58
- 102100036848 C-C motif chemokine 20 Human genes 0.000 claims 2
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 claims 2
- 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 claims 2
- 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 claims 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 108091058543 REG3 Proteins 0.000 claims 1
- 102100027336 Regenerating islet-derived protein 3-alpha Human genes 0.000 claims 1
- 102000000743 Interleukin-5 Human genes 0.000 description 82
- 229940100602 interleukin-5 Drugs 0.000 description 82
- 102000013691 Interleukin-17 Human genes 0.000 description 81
- 108050003558 Interleukin-17 Proteins 0.000 description 81
- 108010074051 C-Reactive Protein Proteins 0.000 description 9
- 102100032752 C-reactive protein Human genes 0.000 description 9
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 8
- 102000004890 Interleukin-8 Human genes 0.000 description 8
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 4
- 229960004909 aminosalicylic acid Drugs 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 229940124624 oral corticosteroid Drugs 0.000 description 4
- 229960005489 paracetamol Drugs 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 230000001861 immunosuppressant effect Effects 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 1
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 1
- 102000008080 Pancreatitis-Associated Proteins Human genes 0.000 description 1
- 108010074467 Pancreatitis-Associated Proteins Proteins 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562235556P | 2015-09-30 | 2015-09-30 | |
| US62/235,556 | 2015-09-30 | ||
| PCT/EP2016/073518 WO2017055611A2 (en) | 2015-09-30 | 2016-09-30 | Methods of using smad7 antisense oligonucleotides based on biomarker expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018531936A JP2018531936A (ja) | 2018-11-01 |
| JP2018531936A5 true JP2018531936A5 (https=) | 2019-11-07 |
Family
ID=57113318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018516772A Pending JP2018531936A (ja) | 2015-09-30 | 2016-09-30 | バイオマーカー発現に基づいてｓｍａｄ７アンチセンスオリゴヌクレオチドを使用する方法 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP3355896A2 (https=) |
| JP (1) | JP2018531936A (https=) |
| CA (1) | CA3000569A1 (https=) |
| WO (1) | WO2017055611A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| ES2627745T3 (es) | 2008-11-13 | 2017-07-31 | Nogra Pharma Limited | Composiciones antisentido, y procedimientos de fabricación y uso de las mismas |
| ES2617200T3 (es) | 2011-09-15 | 2017-06-15 | Nogra Pharma Limited | Procedimientos para supervisar la capacidad de respuesta al tratamiento anti-SMAD7 |
| US10081809B2 (en) | 2012-04-18 | 2018-09-25 | University Of Miami | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| AU2015257589A1 (en) | 2014-05-09 | 2016-11-24 | Nogra Pharma Limited | Methods for treating inflammatory bowel disease |
| WO2016059239A1 (en) | 2014-10-17 | 2016-04-21 | Nogra Pharma Limited | Methods and compositions for treating a subject with a smad7 antisense oligonucleotide |
| JP2019505598A (ja) * | 2016-02-23 | 2019-02-28 | セルジーン アルパイン インベストメント カンパニー Ｉｉ， エルエルシー | Ｓｍａｄ７の阻害を用いて、腸線維症を治療する方法 |
| EP3658155A4 (en) * | 2017-07-28 | 2021-06-30 | Nogra Pharma Limited | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDIC COMPOUNDS |
| WO2020077120A1 (en) * | 2018-10-10 | 2020-04-16 | The Board Of Trustees Of The Leland Stanford Junior University | BLOCKADE OF RGMb FOR TREATING INFLAMMATORY BOWEL DISEASE AND COLITIS |
| CA3120706A1 (en) * | 2018-11-30 | 2020-06-04 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060135610A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Cardiovascular compositions |
| FI20075968A0 (fi) * | 2007-12-28 | 2007-12-28 | Licentia Oy | Menetelmä immunomodulaattorihoitojen tehokkuuden tarkkailemiseksi |
| US20110212104A1 (en) * | 2008-11-03 | 2011-09-01 | Schering Corporation | Inflammatory bowel disease biomarkers and related methods of treatment |
| ES2627745T3 (es) * | 2008-11-13 | 2017-07-31 | Nogra Pharma Limited | Composiciones antisentido, y procedimientos de fabricación y uso de las mismas |
| MX2013012284A (es) * | 2011-04-29 | 2013-11-21 | Bristol Myers Squibb Co | Regimenes de elevacion de dosis del anticuerpo de proteina 10 inducible por interferon gamma (ip-10). |
| ES2617200T3 (es) * | 2011-09-15 | 2017-06-15 | Nogra Pharma Limited | Procedimientos para supervisar la capacidad de respuesta al tratamiento anti-SMAD7 |
-
2016
- 2016-09-30 EP EP16778306.7A patent/EP3355896A2/en not_active Withdrawn
- 2016-09-30 CA CA3000569A patent/CA3000569A1/en not_active Abandoned
- 2016-09-30 JP JP2018516772A patent/JP2018531936A/ja active Pending
- 2016-09-30 WO PCT/EP2016/073518 patent/WO2017055611A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018531936A5 (https=) | ||
| Nagase et al. | Biologics for severe asthma: the real-world evidence, effectiveness of switching, and prediction factors for the efficacy | |
| Sabogal Piñeros et al. | Anti–IL-5 in mild asthma alters rhinovirus-induced macrophage, B-cell, and neutrophil responses (MATERIAL). A placebo-controlled, double-blind study | |
| Tulic et al. | Amb a 1–immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response | |
| Pagnini et al. | Novel pharmacological therapy in inflammatory bowel diseases: beyond anti-tumor necrosis factor | |
| Boyman et al. | Adverse reactions to biologic agents and their medical management | |
| Kaur et al. | Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis | |
| Koczulla et al. | New concepts in asthma: clinical phenotypes and pathophysiological mechanisms | |
| Domingo | Omalizumab for severe asthma: efficacy beyond the atopic patient? | |
| US11400154B2 (en) | Method of treating a localized fibrotic disorder using an IL-33 antagonist | |
| Opina et al. | Phenotype-driven therapeutics in severe asthma | |
| JP2015527364A (ja) | Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法 | |
| JP2017501680A5 (https=) | ||
| CN112807427A (zh) | 一种抗-cxcl10抗体在制备用于治疗受试者中的炎性疾病的用途 | |
| JP2019507755A5 (https=) | ||
| AU2021281359A1 (en) | Markers and cellular antecedents of rheumatoid arthritis flares | |
| Inciarte-Mundo et al. | Reduction of biological agent dose in rheumatic diseases: descriptive analysis of 153 patients in clinical practice conditions | |
| JP2020516289A (ja) | Ｉｌ３３及びｉｌ１ｒｌ１をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 | |
| Nishimoto et al. | Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study | |
| Zhao et al. | Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study | |
| Kook et al. | Serum miR‐214 as a novel biomarker for ankylosing spondylitis | |
| Chang et al. | Regulation of ICAM‐1 expression in gingival fibroblasts infected with high‐glucose‐treated P. gingivalis | |
| RU2020133768A (ru) | Способ лечения астмы или аллергического заболевания | |
| EP4157873A2 (en) | Treatment of cardiometabolic disease with inhibitors of type i interferon signalling | |
| Leath et al. | Novel and emerging therapies for asthma |